We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Harrow Health (HROW - Free Report) is a Zacks Rank #1 (Strong Buy) and it sports an F for Value and a D for Growth. This company is a lot like a “roll up” play in the healthcare space and that diversity could be helping it keep its stock price moving higher. Let’s explore more about this company in this Bull of The Day article.
Description
Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals as subsidiaries. Harrow Health Inc., formerly known as Imprimis Pharmaceuticals Inc., is based in San Diego, United States.
Earnings History
When I look at a stock, the first thing I do is look to see if the company is beating the number. This tells me right away where the market’s expectations have been for the company and how management has communicated to the market. A stock that consistently beats has management communicating expectations to Wall Street that can be achieved. That is what you want to see.
For Harrow Health, I two beats of the Zacks Consensus Estimate that are sandwiched by a miss and a quarter that had no estimate. That is not that great to see, but by itself that is not enough to make the company a Zacks Rank #1 (Strong Buy).
Earnings Estimates Revisions
The Zacks Rank tells us which stocks are seeing earnings estimates move higher.
Over the last 60 days, earning estimates have moved around for HROW.
The full fiscal year 2023 has increased from $0.14 to $0.31 over the last 30 days.
Next fiscal year, has seen estimates spike higher to $1.51 from $0.82 over the same time period.
Those are significant moves higher in a time when so many are calling for recession.
Positive movement in earnings help move this stock to a Zacks Rank #1 (Strong Buy).
Valuation
The valuation for is not for the faint of heart. I see a forward PE 78x which is high no matter who you compare it to. The company showed almost no topline growth in the most recent quarter, but I do see that analysts are looking for 56% revenue growth this year and 31% next year. This name is certainly a good one to keep on your radar screen.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Bull Of The Day: Harrow Health (HROW)
Harrow Health (HROW - Free Report) is a Zacks Rank #1 (Strong Buy) and it sports an F for Value and a D for Growth. This company is a lot like a “roll up” play in the healthcare space and that diversity could be helping it keep its stock price moving higher. Let’s explore more about this company in this Bull of The Day article.
Description
Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals as subsidiaries. Harrow Health Inc., formerly known as Imprimis Pharmaceuticals Inc., is based in San Diego, United States.
Earnings History
When I look at a stock, the first thing I do is look to see if the company is beating the number. This tells me right away where the market’s expectations have been for the company and how management has communicated to the market. A stock that consistently beats has management communicating expectations to Wall Street that can be achieved. That is what you want to see.
For Harrow Health, I two beats of the Zacks Consensus Estimate that are sandwiched by a miss and a quarter that had no estimate. That is not that great to see, but by itself that is not enough to make the company a Zacks Rank #1 (Strong Buy).
Earnings Estimates Revisions
The Zacks Rank tells us which stocks are seeing earnings estimates move higher.
Over the last 60 days, earning estimates have moved around for HROW.
The full fiscal year 2023 has increased from $0.14 to $0.31 over the last 30 days.
Next fiscal year, has seen estimates spike higher to $1.51 from $0.82 over the same time period.
Those are significant moves higher in a time when so many are calling for recession.
Positive movement in earnings help move this stock to a Zacks Rank #1 (Strong Buy).
Valuation
The valuation for is not for the faint of heart. I see a forward PE 78x which is high no matter who you compare it to. The company showed almost no topline growth in the most recent quarter, but I do see that analysts are looking for 56% revenue growth this year and 31% next year. This name is certainly a good one to keep on your radar screen.